These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 20004796)

  • 21. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.
    Keating GM
    Drugs; 2012 May; 72(8):1111-36. PubMed ID: 22571445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
    Schroeder T; Czibere A; Platzbecker U; Bug G; Uharek L; Luft T; Giagounidis A; Zohren F; Bruns I; Wolschke C; Rieger K; Fenk R; Germing U; Haas R; Kröger N; Kobbe G
    Leukemia; 2013 Jun; 27(6):1229-35. PubMed ID: 23314834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Azacitidine. Poor-prognosis myelodysplasia: promising, but more data needed.
    Prescrire Int; 2011 Feb; 20(113):40. PubMed ID: 21488589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on the therapy for myelodysplastic syndrome.
    Kasner MT; Luger SM
    Am J Hematol; 2009 Mar; 84(3):177-86. PubMed ID: 19195035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
    Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
    Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
    Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
    J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
    Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
    Scott LJ
    Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
    Demakos EP; Linebaugh JA
    Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
    Silverman LR; Demakos EP; Peterson BL; Kornblith AB; Holland JC; Odchimar-Reissig R; Stone RM; Nelson D; Powell BL; DeCastro CM; Ellerton J; Larson RA; Schiffer CA; Holland JF
    J Clin Oncol; 2002 May; 20(10):2429-40. PubMed ID: 12011120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
    Hatoum HT; Lin SJ; Buchner D; Kim E
    Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
    Martin MG; Walgren RA; Procknow E; Uy GL; Stockerl-Goldstein K; Cashen AF; Westervelt P; Abboud CN; Kreisel F; Augustin K; Dipersio JF; Vij R
    Am J Hematol; 2009 Sep; 84(9):560-4. PubMed ID: 19650118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.